VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

Area of Science:

• Oncology
• Pulmonary Medicine
• Pharmacology

Background:

• K-ras mutations in lung adenocarcinoma drive tumor angiogenesis and drug resistance.
• Systemic delivery of anti-angiogenic monoclonal antibodies (mAbs) targeting vascular endothelial growth factor (VEGF) has limited efficacy in lung cancer due to poor pulmonary drug penetration.
• The efficacy of anti-VEGF mAbs in K-ras mutated lung adenocarcinomas remains unclear.

Purpose of the Study:

• To investigate the effectiveness of a non-invasive pulmonary delivery route for anti-VEGF mAbs in a K-ras mutated lung cancer mouse model.
• To assess the impact of pulmonary anti-VEGF mAb delivery on tumor progression and angiogenesis.
• To evaluate the pharmacokinetic profile and potential systemic side effects of aerosolized anti-VEGF mAbs.

Main Methods:

• Utilized the K-ras(LA1) mouse model for pulmonary adenocarcinoma.
• Administered anti-VEGF mAbs via an aerosolized pulmonary route.
• Assessed tumor lesion count, malignant progression, and tumor angiogenesis (VEGFR2-dependent).
• Conducted pharmacokinetic analysis of aerosolized anti-VEGF mAbs.

Main Results:

• Pulmonary delivery of anti-VEGF mAbs significantly reduced tumor lesion numbers and inhibited malignant progression.
• The antitumor effect was mediated by VEGFR2-dependent inhibition of blood vessel growth, impairing tumor proliferation.
• Pharmacokinetic analysis revealed minimal systemic absorption of aerosolized anti-VEGF mAbs, suggesting reduced systemic toxicity.

Conclusions:

• Pulmonary administration of anti-VEGF mAbs is a promising therapeutic strategy for K-ras mutated pulmonary adenocarcinoma.
• The aerosol route offers a non-invasive method for targeted delivery, enhancing efficacy and minimizing systemic side effects.
• This approach warrants further investigation for clinical application in lung cancer patients with K-ras mutations.